ConductScience.org, home
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
API referenceFor AI assistants

Trial · NCT02111850

Participant flow66

How many started, completed or left each group, period by period.

1 to 20 of 66

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 1 - 1 X 10^7 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 2 - 3 X 10^7 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1 Dose Level 3 - 1 X 10^8 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 4 - 3 X 10^8 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 5 - 1 X 10^9 Cells + Interleukin-22
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 6 - 3 X 10^9 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 7 - 1 X 10^10 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 8 - 3 X 10^10 Cells + Interleukin-21
Phase 1 Dose EscalationSTARTEDPhase I Dose Escalation Arm 1, Dose Level 9 - 1 X 10^11 Cells + Interleukin-26
Phase 1 Dose EscalationSTARTEDPhase 2 Arm 2, Cohort 1- Maximum Tolerated Dose + Interleukin-2 Other0
Phase 1 Dose EscalationSTARTEDPhase 2 Arm 2, Cohort 2 - Maximum Tolerated Dose + Interleukin-2 Melanoma0
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 1 - 1 X 10^7 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 2 - 3 X 10^7 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1 Dose Level 3 - 1 X 10^8 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 4 - 3 X 10^8 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 5 - 1 X 10^9 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 6 - 3 X 10^9 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 7 - 1 X 10^10 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 8 - 3 X 10^10 Cells + Interleukin-21
Phase 1 Dose EscalationCOMPLETEDPhase I Dose Escalation Arm 1, Dose Level 9 - 1 X 10^11 Cells + Interleukin-26

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02111850/flow

API referenceFor AI assistants